The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera
Lisa Pieri(University of Florence), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi)
Cited by 64
Related Papers
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
|Blood|2014|722
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
|Haematologica|2015|252
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|181
Co‐targeting the PI3K/ <scp>mTOR</scp> and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
|Journal of Cellular and Molecular Medicine|2013|136